nanoTherics offers IP-protected products that support the field of magnetic nanoparticle research and applications.
nanoTherics gene transfection studies have shown a significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst, importantly, maintaining the viability of the transfected cells. These two key attributes afford a significant competitive advantage over currently available systems.nanoTherics’s mission is to position its novel gene transfection technology as the new “gold standard†for transfection, underpinning the research and development of current and future gene therapy programmes.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 28, 2010 | Series Unknown | £1.10M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Mercia Fund Managers | — | Series Unknown |